R&D activity is covered with an option for commercial applications.
Lonza granted UCB a nonexclusive, worldwide license to their GS Gene Expression System™ (GS: glutamine synthetase).
The research evaluation agreement covers the use of the technology for R&D. An option to obtain a license to use the system for commercial purposes is included in the agreement.
“We believe that having UCB select the GS Gene Expression System underscores the importance of this technology for the efficient production of therapeutic antibodies and recombinant proteins,” says Karen Fallen, commercial licensing manager at Lonza.
